Loading chat...
LA HB277
Bill
Status
2/23/2026
Primary Sponsor
Dennis Bamburg
Click for details
AI Summary
-
Educational and marketing materials for prescription drugs provided to healthcare providers must include price information and disclose whether biosimilar or generic alternatives exist for the same disease state
-
Required price disclosures include the date materials were prepared and the average wholesale acquisition cost for a 30-day supply of the drug
-
For drugs designed for therapy lasting less than 30 days, materials must show the proposed duration and average wholesale price for that specific period
-
Violations constitute a prohibited practice under Louisiana's Unfair Trade Practices and Consumer Protection Law (R.S. 51:1401 et seq.) and are subject to enforcement under that law
-
Creates new Part VI-C of Chapter 20 of Title 37 (R.S. 37:1742.11) in Louisiana Revised Statutes
Legislative Description
Requires educational or marketing materials for prescription drugs directed to healthcare providers to include price information (OR SEE FISC NOTE GF EX)
DRUGS/PRESCRIPTION
Last Action
Read by title, under the rules, referred to the Committee on Health and Welfare.
3/9/2026